Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 3Breast Neoplasms 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms 1NSCLC 1Mucopolysaccharidosis I 1Metastatic Castration-resistant Prostate Cancer 1Metabolism, Inborn Errors 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Liposarcoma 1Leukemia 1Immunologic Deficiency Syndromes 1Immunoblastic Lymphadenopathy 1Hemoglobinopathies 1Disease Progression 1Congenital Bone Marrow Failure Syndromes 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma in Situ 1Bone Marrow Failure Disorders 1Anemia, Refractory, with Excess of Blasts 1Adenocarcinoma 1

Interventions

Gemcitabine 6Docetaxel 3durvalumab 2Mitomycin 2viscum album peptide 1tremelimumab 1pembrolizumab 1erdafitinib 1avelumab 1VPM1002 recombinant BCG vaccine 1Neoadjuvant Therapy 1Monatide (IMS 3015) 1Mitozytrex 1House Calls 1Home Care Services 1Dihematoporphyrin Ether 1DDMS 1Cystoscopy 1Clinical Trials, Phase II as Topic 1Clinical Trials, Phase I as Topic 1BCG Vaccine 1Administration, Intravesical 1ALT-803 1ALT-801 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Non-Muscle Invasive Bladder Neoplasms × Clinical Trials, Phase I as Topic × Clear all
NCT04752722 2026-04-30

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

enGene, Inc.

Phase 1/2 Recruiting
350 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

Data powered by HemOnc (CC BY 4.0) Colophon âš¡